Tvardi Therapeutics is trading at $1.85, up 6.02%, in a move that appears primarily sector-driven, with biotech ETF XBI up 2.75% during regular trading.
- No fresh company-specific announcement dated September 2, 2026 was identified; the latest update announced upcoming healthcare-investor events.
- Patent-related gains in Purple Biotech also supported broader positive biotech momentum.
- Major U.S. indexes were modestly higher; no major scheduled economic release offered a stronger market-wide catalyst.